Market Overview:
The global direct oral anticoagulant market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of thromboembolic disorders, rising geriatric population, and technological advancements in the field of anticoagulants. Based on type, the global direct oral anticoagulant market is segmented into apixaban, dabigatran, rivaroxaban, and edoxaban. Apixaban held a major share of the global direct oral anticoagulant market in 2017 and is expected to maintain its dominance during the forecast period. This can be attributed to its high efficacy and safety profile as compared to other drugs in this class. Rivaroxaban held second largest share of this market in 2017 due to its high prevalence among patients with atrial fibrillation (AF) across all geographies studied herein.
Product Definition:
A direct oral anticoagulant, also called a novel oral anticoagulant (NOAC), is an orally administered drug that inhibits blood clotting. They are used to prevent or treat thromboembolic disorders such as venous thromboembolism, pulmonary embolism, and atrial fibrillation.
Apixaban:
Apixaban is a prescription drug used to prevent blood clots. It's main ingredient is xanthine oxidase inhibitor. It works by reducing the ability of blood to clot and also blocks some of the ways that vitamin K does it in the body, which prevents new clots from forming.
Dabigatran:
Dabigatran is a new oral anticoagulant drug developed by Bayer. It is an intravenous heparin-like drug that works through direct thrombin inhibition. Dabigatran was approved in Europe and Japan in 2015 and 2016 respectively, for the treatment of atrial fibrillation.
Application Insights:
The application segment is divided into hospitals, pharmacies, and online pharmacies. The hospitals segment dominated the market in 2017 owing to factors such as a high prevalence of blood clots in patients suffering from various diseases and the presence of a large number of hospitals that are equipped with anticoagulants for treatment. Direct oral anticoagulants are expensive drugs; therefore, they cannot be used by all patients without insurance coverage. Therefore, before prescribing these drugs to any patient or after consultation with a healthcare professional, companies send their representatives to seek approval from hospital authorities about covering the cost of medication.
Pharmacies also accounted for a significant share due to availability of direct oral anticoagulant tablets and liquid at low costs through prescription rather than buying them directly from medical stores or drugstores.
Regional Analysis:
North America dominated the global market in 2017. This is due to the presence of a large patient pool and well-established healthcare infrastructure. Moreover, favorable reimbursement policies for OPA are also expected to contribute towards its high adoption rate in this region. In addition, increasing FDA approvals for new products are further expected to drive growth during the forecast period.
Growth Factors:
- Increasing incidence of thromboembolic disorders: The global incidence of thromboembolic disorders is increasing at a rapid pace. This is primarily attributed to the changing lifestyle and dietary habits, growing aging population, and increasing prevalence of chronic diseases. This is expected to drive the demand for direct oral anticoagulants in the coming years.
- Growing awareness about benefits of early treatment: There is a growing awareness among healthcare professionals and patients about the benefits of early treatment for thromboembolic disorders. Direct oral anticoagulants offer an effective and convenient mode of therapy for early treatment, which is expected to boost their demand in the coming years.
- Technological advancements: The development of novel direct oral anticoagulants with improved safety and efficacy profiles is likely to spur growth in this market during the forecast period. These drugs are being increasingly used as alternatives to warfarin due to their better patient compliance rates and fewer drug interactions compared with warfarin therapy regimens.
Scope Of The Report
Report Attributes
Report Details
Report Title
Direct Oral Anticoagulant Market Research Report
By Type
Apixaban, Dabigatran, Rivaroxaban, Edoxaban
By Application
Hospitals Pharmacies, Drug Stores, Online Pharmacies
By Companies
Bristol-Meyers Squibb Co, Pfizer Inc., Boehringer Ingelheim Pharmaceuticals, Inc, Janssen Pharmaceuticals, Inc., Bayer AG, Teva Pharmaceutical Industries Ltd, Pab Organics Private Limited, Daiichi Sankyo Company, Limited
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Direct Oral Anticoagulant Market Report Segments:
The global Direct Oral Anticoagulant market is segmented on the basis of:
Types
Apixaban, Dabigatran, Rivaroxaban, Edoxaban
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals Pharmacies, Drug Stores, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Meyers Squibb Co
- Pfizer Inc.
- Boehringer Ingelheim Pharmaceuticals, Inc
- Janssen Pharmaceuticals, Inc.
- Bayer AG
- Teva Pharmaceutical Industries Ltd
- Pab Organics Private Limited
- Daiichi Sankyo Company, Limited
Highlights of The Direct Oral Anticoagulant Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Apixaban
- Dabigatran
- Rivaroxaban
- Edoxaban
- By Application:
- Hospitals Pharmacies
- Drug Stores
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Direct Oral Anticoagulant Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Direct oral anticoagulants are medications that help to prevent blood from clotting. They work by interfering with the process of coagulation.
Some of the major players in the direct oral anticoagulant market are Bristol-Meyers Squibb Co, Pfizer Inc., Boehringer Ingelheim Pharmaceuticals, Inc, Janssen Pharmaceuticals, Inc., Bayer AG, Teva Pharmaceutical Industries Ltd, Pab Organics Private Limited, Daiichi Sankyo Company, Limited.
The direct oral anticoagulant market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Direct Oral Anticoagulant Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Direct Oral Anticoagulant Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Direct Oral Anticoagulant Market - Supply Chain
4.5. Global Direct Oral Anticoagulant Market Forecast
4.5.1. Direct Oral Anticoagulant Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Direct Oral Anticoagulant Market Size (000 Units) and Y-o-Y Growth
4.5.3. Direct Oral Anticoagulant Market Absolute $ Opportunity
5. Global Direct Oral Anticoagulant Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Direct Oral Anticoagulant Market Size and Volume Forecast by Type
5.3.1. Apixaban
5.3.2. Dabigatran
5.3.3. Rivaroxaban
5.3.4. Edoxaban
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Direct Oral Anticoagulant Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Direct Oral Anticoagulant Market Size and Volume Forecast by Application
6.3.1. Hospitals Pharmacies
6.3.2. Drug Stores
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Direct Oral Anticoagulant Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Direct Oral Anticoagulant Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Direct Oral Anticoagulant Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Direct Oral Anticoagulant Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Direct Oral Anticoagulant Demand Share Forecast, 2019-2026
9. North America Direct Oral Anticoagulant Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Direct Oral Anticoagulant Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Direct Oral Anticoagulant Market Size and Volume Forecast by Application
9.4.1. Hospitals Pharmacies
9.4.2. Drug Stores
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Direct Oral Anticoagulant Market Size and Volume Forecast by Type
9.7.1. Apixaban
9.7.2. Dabigatran
9.7.3. Rivaroxaban
9.7.4. Edoxaban
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Direct Oral Anticoagulant Demand Share Forecast, 2019-2026
10. Latin America Direct Oral Anticoagulant Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Direct Oral Anticoagulant Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Direct Oral Anticoagulant Market Size and Volume Forecast by Application
10.4.1. Hospitals Pharmacies
10.4.2. Drug Stores
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Direct Oral Anticoagulant Market Size and Volume Forecast by Type
10.7.1. Apixaban
10.7.2. Dabigatran
10.7.3. Rivaroxaban
10.7.4. Edoxaban
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Direct Oral Anticoagulant Demand Share Forecast, 2019-2026
11. Europe Direct Oral Anticoagulant Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Direct Oral Anticoagulant Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Direct Oral Anticoagulant Market Size and Volume Forecast by Application
11.4.1. Hospitals Pharmacies
11.4.2. Drug Stores
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Direct Oral Anticoagulant Market Size and Volume Forecast by Type
11.7.1. Apixaban
11.7.2. Dabigatran
11.7.3. Rivaroxaban
11.7.4. Edoxaban
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Direct Oral Anticoagulant Demand Share, 2019-2026
12. Asia Pacific Direct Oral Anticoagulant Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Direct Oral Anticoagulant Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Direct Oral Anticoagulant Market Size and Volume Forecast by Application
12.4.1. Hospitals Pharmacies
12.4.2. Drug Stores
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Direct Oral Anticoagulant Market Size and Volume Forecast by Type
12.7.1. Apixaban
12.7.2. Dabigatran
12.7.3. Rivaroxaban
12.7.4. Edoxaban
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Direct Oral Anticoagulant Demand Share, 2019-2026
13. Middle East & Africa Direct Oral Anticoagulant Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Direct Oral Anticoagulant Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Direct Oral Anticoagulant Market Size and Volume Forecast by Application
13.4.1. Hospitals Pharmacies
13.4.2. Drug Stores
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Direct Oral Anticoagulant Market Size and Volume Forecast by Type
13.7.1. Apixaban
13.7.2. Dabigatran
13.7.3. Rivaroxaban
13.7.4. Edoxaban
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Direct Oral Anticoagulant Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Direct Oral Anticoagulant Market: Market Share Analysis
14.2. Direct Oral Anticoagulant Distributors and Customers
14.3. Direct Oral Anticoagulant Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bristol-Meyers Squibb Co
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Pfizer Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Boehringer Ingelheim Pharmaceuticals, Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Janssen Pharmaceuticals, Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bayer AG
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Teva Pharmaceutical Industries Ltd
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Pab Organics Private Limited
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Daiichi Sankyo Company, Limited
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
